Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

M. A. Dimopoulos; E Kastritis; E Terpos; H Nahi; H. Goldschmidt; J Hillengass; X Leleu; Meral Beksac; M Alsina; Albert Oriol; M. Cavo; E. M. Ocio; M. V. Mateos; E K O'Donnell; R Vij; Henk M Lokhorst; Niels W C J van de Donk; J. Cam-min; Torrance Mark; I Turesson; Markus Hansson; S. Jagannath; M Delforge; Charalampia Kyriakou; P Hari; U. H. Mellqvist; S Z Usmani; D Dytfeld; Ashraf Z Badros; P R Otero; C Shustik; D Waller; W-J Chng; Shoichi Ozaki; Javier de la Rubia; H S Eom; L Rosinol; J. J. Lahuerta; A Sureda; J. S. Kim; B. G. M. Durie

doi:10.1038/leu.2017.138

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

M. A. Dimopoulos, E Kastritis, E Terpos, H Nahi, H. Goldschmidt, J Hillengass, X Leleu, Meral Beksac, M Alsina, Albert Oriol, M. Cavo, E. M. Ocio, M. V. Mateos, E K O'Donnell, R Vij, Henk M Lokhorst, Niels W C J van de Donk, J. Cam-min, Torrance Mark, I TuressonMarkus Hansson, S. Jagannath, M Delforge, Charalampia Kyriakou, P Hari, U. H. Mellqvist, S Z Usmani, D Dytfeld, Ashraf Z Badros, P R Otero, C Shustik, D Waller, W-J Chng, Shoichi Ozaki, Javier de la Rubia, H S Eom, L Rosinol, J. J. Lahuerta, A Sureda, J. S. Kim, B. G. M. Durie

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction of new myeloma therapies offers new options for patients refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this multicenter study, patients with relapsed multiple myeloma, who have received at least three prior lines of therapy, are refractory to both an IMiD (lenalidomide or pomalidomide) and a PI (bortezomib or carfilzomib), and have been exposed to an alkylating agent were identified. The time patients met the above criteria was defined as time zero (T0). Five hundred and forty-three patients diagnosed between 2006 and 2014 were enrolled in this study. Median age at T0 was 62 years (range 31-87); 61% were males. The median duration between diagnosis and T0 was 3.1 years. The median number of lines of therapy before T0 was 4 (range 3-13). The median overall survival (OS) from T0 for the entire cohort was 13 (95% confidence interval (CI) 11, 15) months. At least one regimen recorded after T0 in 462 (85%) patients, with a median (95% CI) progression-free survival and OS from T0 of 5 (4, 6), and 15.2 (13, 17) months, respectively. The study provides the expected outcome of relapsed multiple myeloma that is refractory to a PI and an IMiD, a benchmark for comparison of new therapies being evaluated.Leukemia advance online publication, 16 June 2017; doi:10.1038/leu.2017.138.

Original language	English
Pages (from-to)	2443-2448
Journal	Leukemia
Volume	31
Early online date	2017 May 12
DOIs	https://doi.org/10.1038/leu.2017.138
Publication status	Published - 2017

Subject classification (UKÄ)

Hematology

Free keywords

Journal Article

Access to Document

10.1038/leu.2017.138

Cite this

Dimopoulos, M. A., Kastritis, E., Terpos, E., Nahi, H., Goldschmidt, H., Hillengass, J., Leleu, X., Beksac, M., Alsina, M., Oriol, A., Cavo, M., Ocio, E. M., Mateos, M. V., O'Donnell, E. K., Vij, R., Lokhorst, H. M., van de Donk, N. W. C. J., Cam-min, J., Mark, T., ... Durie, B. G. M. (2017). Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia, 31, 2443-2448. https://doi.org/10.1038/leu.2017.138

@article{8b12a008d2564956a9ef6eb26cbb9f35,

title = "Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study",

abstract = "Introduction of new myeloma therapies offers new options for patients refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this multicenter study, patients with relapsed multiple myeloma, who have received at least three prior lines of therapy, are refractory to both an IMiD (lenalidomide or pomalidomide) and a PI (bortezomib or carfilzomib), and have been exposed to an alkylating agent were identified. The time patients met the above criteria was defined as time zero (T0). Five hundred and forty-three patients diagnosed between 2006 and 2014 were enrolled in this study. Median age at T0 was 62 years (range 31-87); 61% were males. The median duration between diagnosis and T0 was 3.1 years. The median number of lines of therapy before T0 was 4 (range 3-13). The median overall survival (OS) from T0 for the entire cohort was 13 (95% confidence interval (CI) 11, 15) months. At least one regimen recorded after T0 in 462 (85%) patients, with a median (95% CI) progression-free survival and OS from T0 of 5 (4, 6), and 15.2 (13, 17) months, respectively. The study provides the expected outcome of relapsed multiple myeloma that is refractory to a PI and an IMiD, a benchmark for comparison of new therapies being evaluated.Leukemia advance online publication, 16 June 2017; doi:10.1038/leu.2017.138.",

keywords = "Journal Article",

author = "Dimopoulos, {M. A.} and E Kastritis and E Terpos and H Nahi and H. Goldschmidt and J Hillengass and X Leleu and Meral Beksac and M Alsina and Albert Oriol and M. Cavo and Ocio, {E. M.} and Mateos, {M. V.} and O'Donnell, {E K} and R Vij and Lokhorst, {Henk M} and {van de Donk}, {Niels W C J} and J. Cam-min and Torrance Mark and I Turesson and Markus Hansson and S. Jagannath and M Delforge and Charalampia Kyriakou and P Hari and Mellqvist, {U. H.} and Usmani, {S Z} and D Dytfeld and Badros, {Ashraf Z} and Otero, {P R} and C Shustik and D Waller and W-J Chng and Shoichi Ozaki and {de la Rubia}, Javier and Eom, {H S} and L Rosinol and Lahuerta, {J. J.} and A Sureda and Kim, {J. S.} and Durie, {B. G. M.}",

year = "2017",

doi = "10.1038/leu.2017.138",

language = "English",

volume = "31",

pages = "2443--2448",

journal = "Leukemia",

issn = "1476-5551",

publisher = "Nature Publishing Group",

}

Dimopoulos, MA, Kastritis, E, Terpos, E, Nahi, H, Goldschmidt, H, Hillengass, J, Leleu, X, Beksac, M, Alsina, M, Oriol, A, Cavo, M, Ocio, EM, Mateos, MV, O'Donnell, EK, Vij, R, Lokhorst, HM, van de Donk, NWCJ, Cam-min, J, Mark, T, Turesson, I , Hansson, M, Jagannath, S, Delforge, M, Kyriakou, C, Hari, P, Mellqvist, UH, Usmani, SZ, Dytfeld, D, Badros, AZ, Otero, PR, Shustik, C, Waller, D, Chng, W-J, Ozaki, S, de la Rubia, J, Eom, HS, Rosinol, L, Lahuerta, JJ, Sureda, A, Kim, JS & Durie, BGM 2017, 'Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study', Leukemia, vol. 31, pp. 2443-2448. https://doi.org/10.1038/leu.2017.138

TY - JOUR

T1 - Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors

T2 - a multicenter IMWG study

AU - Dimopoulos, M. A.

AU - Kastritis, E

AU - Terpos, E

AU - Nahi, H

AU - Goldschmidt, H.

AU - Hillengass, J

AU - Leleu, X

AU - Beksac, Meral

AU - Alsina, M

AU - Oriol, Albert

AU - Cavo, M.

AU - Ocio, E. M.

AU - Mateos, M. V.

AU - O'Donnell, E K

AU - Vij, R

AU - Lokhorst, Henk M

AU - van de Donk, Niels W C J

AU - Cam-min, J.

AU - Mark, Torrance

AU - Turesson, I

AU - Hansson, Markus

AU - Jagannath, S.

AU - Delforge, M

AU - Kyriakou, Charalampia

AU - Hari, P

AU - Mellqvist, U. H.

AU - Usmani, S Z

AU - Dytfeld, D

AU - Badros, Ashraf Z

AU - Otero, P R

AU - Shustik, C

AU - Waller, D

AU - Chng, W-J

AU - Ozaki, Shoichi

AU - de la Rubia, Javier

AU - Eom, H S

AU - Rosinol, L

AU - Lahuerta, J. J.

AU - Sureda, A

AU - Kim, J. S.

AU - Durie, B. G. M.

PY - 2017

Y1 - 2017

N2 - Introduction of new myeloma therapies offers new options for patients refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this multicenter study, patients with relapsed multiple myeloma, who have received at least three prior lines of therapy, are refractory to both an IMiD (lenalidomide or pomalidomide) and a PI (bortezomib or carfilzomib), and have been exposed to an alkylating agent were identified. The time patients met the above criteria was defined as time zero (T0). Five hundred and forty-three patients diagnosed between 2006 and 2014 were enrolled in this study. Median age at T0 was 62 years (range 31-87); 61% were males. The median duration between diagnosis and T0 was 3.1 years. The median number of lines of therapy before T0 was 4 (range 3-13). The median overall survival (OS) from T0 for the entire cohort was 13 (95% confidence interval (CI) 11, 15) months. At least one regimen recorded after T0 in 462 (85%) patients, with a median (95% CI) progression-free survival and OS from T0 of 5 (4, 6), and 15.2 (13, 17) months, respectively. The study provides the expected outcome of relapsed multiple myeloma that is refractory to a PI and an IMiD, a benchmark for comparison of new therapies being evaluated.Leukemia advance online publication, 16 June 2017; doi:10.1038/leu.2017.138.

AB - Introduction of new myeloma therapies offers new options for patients refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this multicenter study, patients with relapsed multiple myeloma, who have received at least three prior lines of therapy, are refractory to both an IMiD (lenalidomide or pomalidomide) and a PI (bortezomib or carfilzomib), and have been exposed to an alkylating agent were identified. The time patients met the above criteria was defined as time zero (T0). Five hundred and forty-three patients diagnosed between 2006 and 2014 were enrolled in this study. Median age at T0 was 62 years (range 31-87); 61% were males. The median duration between diagnosis and T0 was 3.1 years. The median number of lines of therapy before T0 was 4 (range 3-13). The median overall survival (OS) from T0 for the entire cohort was 13 (95% confidence interval (CI) 11, 15) months. At least one regimen recorded after T0 in 462 (85%) patients, with a median (95% CI) progression-free survival and OS from T0 of 5 (4, 6), and 15.2 (13, 17) months, respectively. The study provides the expected outcome of relapsed multiple myeloma that is refractory to a PI and an IMiD, a benchmark for comparison of new therapies being evaluated.Leukemia advance online publication, 16 June 2017; doi:10.1038/leu.2017.138.

KW - Journal Article

U2 - 10.1038/leu.2017.138

DO - 10.1038/leu.2017.138

M3 - Article

C2 - 28620163

SN - 1476-5551

VL - 31

SP - 2443

EP - 2448

JO - Leukemia

JF - Leukemia

ER -

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Abstract

Subject classification (UKÄ)

Free keywords

Access to Document

Fingerprint

Cite this